EMA Authorised: Vitrakvi (larotrectinib sulfate) — Bayer AG

View source ↗

Summary

The EMA authorises Vitrakvi (larotrectinib sulfate) from Bayer AG with conditional approval for abdominal neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abdominal Neoplasms

Drugs mentioned

• Vitrakvi (larotrectinib)

Snippet

Status: Authorised. Therapeutic area: Abdominal Neoplasms. MAH: Bayer AG. Decision date: 08/07/2026. Conditional approval